Suzhou Puhe Biopharma Co., Ltd. was founded in April 2021, jointly incubated by a well-known domestic pharmaceutical enterprise and the pharmaceutical industry fund "Shiyu Investment". We focus on the development of small-molecule innovative drugs for oncology, immunological disorders, and metabolic diseases, and are committed to becoming a leading BioPharma company rooted in China and oriented toward the global market.

Guided by a strategy of addressing differentiated clinical needs, we prioritize cancers with high incidence and mortality rates, such as lung cancer, pancreatic cancer, and gastrointestinal cancers, as well as areas with high clinically unmet needs including immunological disorders and metabolic diseases. With a comprehensive layout guided by scientific and industrial thinking, we actively explore R&D opportunities for innovative small-molecule drugs through independent research and in-licensing, and integrate resources to accelerate the company’s industrialization drive.

We have built a distinctive innovative small-molecule drug discovery and development platform by anchoring to molecular targets and integrating AI technology, with development capabilities to cover the entire development spectrum, including target discovery, molecular structure design, preclinical drug development, regulatory filing, clinical trial execution, and product manufacturing. Our pipeline spans multiple high-barrier development areas, such as next-generation kinase inhibitors, allosteric inhibitors, synthetic lethality, PROTACs, and molecular glues. Several drug candidates are in the global first tier in terms of development progress, with superior molecular properties and strong international competitiveness.